CD34+CD38− leukemic stem cell frequency to predict outcome in acute myeloid leukemia-Reference-Cited by-同舟云学术

CD34+CD38− leukemic stem cell frequency to predict outcome in acute myeloid leukemia

Published:2018-12-12 Issue:5 Volume:33 Page:1102-1112
ISSN:0887-6924
Container-title:Leukemia
language:en
Short-container-title:Leukemia

Author:

Zeijlemaker Wendelien,Grob Tim,Meijer Rosa,Hanekamp Diana,Kelder Angèle,Carbaat-Ham Jannemieke C.,Oussoren-Brockhoff Yvonne J. M.,Snel Alexander N.,Veldhuizen Dennis,Scholten Willemijn J.,Maertens Johan,Breems Dimitri A.,Pabst Thomas,Manz Markus G.^ORCID,van der Velden Vincent H. J.,Slomp Jennichjen,Preijers Frank,Cloos Jacqueline,van de Loosdrecht Arjan A.,Löwenberg Bob,Valk Peter J. M.,Jongen-Lavrencic Mojca,Ossenkoppele Gert J.,Schuurhuis Gerrit J.

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Cancer Research,Hematology

Link

http://www.nature.com/articles/s41375-018-0326-3.pdf

Reference40 articles.

1. Hokland P, Ommen HB, Mulè MP, Hourigan CS. Advancing the Mrd concept in acute myeloid. Semin Hematol. 2015;52:184–92.

2. Terwijn M, van Putten WLJ, Kelder A, van der Velden VHJ, Brooimans RA, Pabst T, et al. High prognostic impact of flow cytometric minimal residual disease detection in acute myeloid leukemia: data from the HOVON/SAKK AML 42A study. J Clin Oncol. 2013;31:3889–97.

3. Freeman SD, Virgo P, Couzens S, Grimwade D, Russell N, Hills RK, et al. Prognostic relevance of treatment response measured by flow cytometric residual disease detection in older patients with acute myeloid leukemia. J Clin Oncol. 2013;31:4123–31.

4. Loken MR, Alonzo Ta, Pardo L, Gerbing RB, Raimondi SC, Hirsch BA, et al. Residual disease detected by multidimensional flow cytometry signifies high relapse risk in patients with de novo acute myeloid leukemia: a report from Children’s Oncology Group. Blood. 2012;120:1581–8.

5. Zhu H, Zhang X, Qin Y, Liu D, Jiang H, Chen H, et al. MRD-directed risk stratification treatment may improve outcomes of t(8 ;21) AML in the first complete remission: results from the AML05 multicenter trial. Blood. 2013;121:4056–62.

Cited by 141 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. OMIP‐106: A 30‐color panel for analysis of check‐point inhibitory networks in the bone marrow of acute myeloid leukemia patients;Cytometry Part A;2024-08-27

2. The role of the primitive marker CD133 in CD34‐negative acute myeloid leukemia for the detection of leukemia stem cells;Cytometry Part B: Clinical Cytometry;2024-08-23

3. ZMAT3 participated in benzene-caused disruption in self-renewal and differentiation of hematopoietic stem cells via TNF-α/NF-κB pathway;Food and Chemical Toxicology;2024-08

4. Measurable residual disease (MRD)-testing in haematological cancers: A giant leap forward or sideways?;Blood Reviews;2024-08

5. Immunophenotypic features of early haematopoietic and leukaemia stem cells;International Journal of Laboratory Hematology;2024-07-24